share_log

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K: Current report

Avenue Therapeutics | 8-K:重大事件
美股sec公告 ·  03/29 14:43
Moomoo AI 已提取核心訊息
Avenue Therapeutics, Inc. reported on March 29, 2024, that it has received a delisting notice from Nasdaq due to the company's failure to maintain the minimum bid price requirement. The company's common stock had been trading below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Although a 180-day grace period ending March 25, 2024, was granted to regain compliance, Avenue Therapeutics was unable to meet the requirement. Despite the delisting determination issued on March 26, 2024, the company's listing status remains unaffected for now, following a decision by the Nasdaq Hearings Panel on March 11, 2024, which granted an extension until May 20, 2024, for the company to demonstrate compliance with the minimum stockholders’ equity and bid price rules. Avenue Therapeutics is exploring all available options to regain compliance, but there is no guarantee of success.
Avenue Therapeutics, Inc. reported on March 29, 2024, that it has received a delisting notice from Nasdaq due to the company's failure to maintain the minimum bid price requirement. The company's common stock had been trading below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Although a 180-day grace period ending March 25, 2024, was granted to regain compliance, Avenue Therapeutics was unable to meet the requirement. Despite the delisting determination issued on March 26, 2024, the company's listing status remains unaffected for now, following a decision by the Nasdaq Hearings Panel on March 11, 2024, which granted an extension until May 20, 2024, for the company to demonstrate compliance with the minimum stockholders’ equity and bid price rules. Avenue Therapeutics is exploring all available options to regain compliance, but there is no guarantee of success.
Avenue Therapeutics, Inc.於2024年3月29日報告稱,由於該公司未能維持最低出價要求,它已收到納斯達克的退市通知。該公司的普通股連續30個工作日交易價格低於每股1.00美元,違反了納斯達克上市規則5550(a)(2)。儘管批准了截至2024年3月25日的180天寬限期以恢復合規,但Avenue Therapeutics仍無法滿足這一要求。儘管2024年3月26日發佈了退市決定,但該公司的上市狀況目前仍未受到影響,此前納斯達克聽證會小組於2024年3月11日作出決定,批准將公司證明遵守最低股東權益和出價規則的期限延長至2024年5月20日。Avenue Therapeutics正在探索所有可用的選擇以恢復合規性,但無法保證成功。
Avenue Therapeutics, Inc.於2024年3月29日報告稱,由於該公司未能維持最低出價要求,它已收到納斯達克的退市通知。該公司的普通股連續30個工作日交易價格低於每股1.00美元,違反了納斯達克上市規則5550(a)(2)。儘管批准了截至2024年3月25日的180天寬限期以恢復合規,但Avenue Therapeutics仍無法滿足這一要求。儘管2024年3月26日發佈了退市決定,但該公司的上市狀況目前仍未受到影響,此前納斯達克聽證會小組於2024年3月11日作出決定,批准將公司證明遵守最低股東權益和出價規則的期限延長至2024年5月20日。Avenue Therapeutics正在探索所有可用的選擇以恢復合規性,但無法保證成功。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息